Now Approved for Lupus Nephritis
BENLYSTA is Designed
for Lupus
BENLYSTA is indicated for patients aged ≥5 with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and patients aged ≥18 with active lupus nephritis receiving standard therapy. The subcutaneous (SC) formulation is approved for patients aged ≥18. BENLYSTA is not recommended in patients with severe active central nervous system lupus or in combination with other biologics.
SEE THE SLE TRIAL RESULTS:1-3
Disease activity
Primary endpoint
Risk of severe flare
Secondary endpoint
Steroid dose
Secondary endpoint
You can now use BENLYSTA for your patients with lupus nephritis
Based on the results of BLISS-LN, BENLYSTA can now be used in patients with lupus nephritis.
Established Efficacy in SLE
BENLYSTA has demonstrated efficacy across a variety of patient types.
Real-World Evidence
Find out about BENLYSTA and organ damage accrual in the real-world setting.
Dosing Flexibility
BENLYSTA is available in multiple formulations for adult patients. Talk to your patients about which formulation is right for them.